Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis.
Adipokines
Adiponectin
Metabolic syndrome
Resistin
Systemic lupus erythematosus
Systemic sclerosis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
08
08
2020
accepted:
04
04
2021
revised:
09
03
2021
pubmed:
12
4
2021
medline:
29
9
2021
entrez:
11
4
2021
Statut:
ppublish
Résumé
Aims of study were to evaluate the prevalence of metabolic syndrome (MetS) in systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) patients and to evaluate serum level of adipokines in SLE and SSc patients with and without MetS. Fifty SLE patients and 85 SSc patients were enrolled. The diagnosis of MetS was made according to the criteria of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III. Clinical assessment and serum levels of adiponectin and resistin were evaluate in SLE and SSc patients. Prevalence of MetS was significantly (p<0.0001) higher in SLE patients than SSc patients (36% vs 10.6%). Median values of resistin were significantly (p<0.001) higher in SLE patients with MetS than SLE patients without MetS [4.01 ng/mL (2.7-4.5) vs 1.92 ng/mL (1.2-3)]. Median values of adiponectin were significantly (p<0.05) lower in SLE patients with MetS than SLE patients without MetS [5.64 ng/mL (4.96-8) vs 8.38 ng/mL (6.54-11.01)]. Systemic Lupus Erythematosus Activity Index [8 (6-12) vs 10 (6-13), p<0.01] and Systemic Damage Index [2 (1-3) vs 2 (0-3), p<0.001] were significantly higher in MetS patients than in patients without MetS. In SSc, the median value of disease severity scale was significantly higher (p<0.05) in MetS patients than in patients without MetS [7 (5-7) vs 5 (3-6)]. Prevalence of MetS is higher in SLE patients. In SLE patients, MetS showed an association with adipokine levels and inflammation/activity disease scores. In SSc patients, MetS was associated with severity of disease. Key Points • Prevalence of metabolic syndrome is higher in SLE patients than SSc patients. • Resistin is higher in SLE patients with metabolic syndrome. • Adineponectin is lower in SLE patients with metabolic syndrome. • Disease severity scale is higher in SSc patients with metabolic syndrome.
Identifiants
pubmed: 33839992
doi: 10.1007/s10067-021-05731-6
pii: 10.1007/s10067-021-05731-6
pmc: PMC8463337
doi:
Substances chimiques
Adipokines
0
Resistin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4253-4258Informations de copyright
© 2021. The Author(s).
Références
Metab Syndr Relat Disord. 2018 Oct;16(8):395-405
pubmed: 30063173
Int J Med Sci. 2016 Jan 01;13(1):25-38
pubmed: 26816492
Lupus. 2011 Dec;20(14):1459-65
pubmed: 21893561
Rev Med Inst Mex Seguro Soc. 2015 Jul-Aug;53(4):476-83
pubmed: 26177436
BMC Public Health. 2016 Apr 01;16:296
pubmed: 27039079
Diabetes Care. 2001 Apr;24(4):683-9
pubmed: 11315831
J Rheumatol. 2003 Sep;30(9):1955-9
pubmed: 12966597
Expert Rev Clin Immunol. 2019 Jul;15(7):765-775
pubmed: 31094570
J Rheumatol. 2002 Feb;29(2):288-91
pubmed: 11838846
J Rheumatol. 1999 Oct;26(10):2159-67
pubmed: 10529133
Pharmacol Res. 2018 Jul;133:277-288
pubmed: 29382608
Lancet. 2005 Apr 16-22;365(9468):1415-28
pubmed: 15836891
Ann Rheum Dis. 2007 Feb;66(2):208-14
pubmed: 16901956
Diabetes Metab Syndr. 2018 Apr - Jun;12(2):195-201
pubmed: 29203060
Rheumatology (Oxford). 2009 May;48(5):497-501
pubmed: 19269958
Rheumatology (Oxford). 2014 Apr;53(4):704-13
pubmed: 24357811
Lancet. 2014 Nov 22;384(9957):1878-1888
pubmed: 24881804
J Atheroscler Thromb. 2011;18(7):545-50
pubmed: 21551960
Ann Rheum Dis. 2017 Jan;76(1):270-276
pubmed: 27621285
Rheumatology (Oxford). 2006 Oct;45 Suppl 4:iv43-6
pubmed: 16980724
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Circulation. 2007 Jul 24;116(4):419-26
pubmed: 17620509
Cytokine. 2019 May;117:41-49
pubmed: 30784899
Maturitas. 2010 Feb;65(2):117-21
pubmed: 20031349
J Rheumatol. 1995 Jul;22(7):1281-5
pubmed: 7562759
Arch Dermatol Res. 2019 May;311(4):251-263
pubmed: 30806766
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Natl Health Stat Report. 2009 May 5;(13):1-7
pubmed: 19634296
Autoimmunity. 2009 May;42(4):272-4
pubmed: 19811274
Ann Rheum Dis. 2015 Aug;74(8):1530-6
pubmed: 24692585
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):792-799
pubmed: 30641809
Eur J Nutr. 2012 Aug;51(5):513-28
pubmed: 22584415
Pharmacol Ther. 2020 Oct;214:107614
pubmed: 32592715
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
J Rheumatol. 2006 Aug;33(8):1545-52
pubmed: 16881111
Circ J. 2004 Nov;68(11):975-81
pubmed: 15502375
Eur J Prev Cardiol. 2015 Apr;22(4):486-91
pubmed: 24647805
J Rheumatol. 2009 Feb;36(2):295-7
pubmed: 19132788
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Rheumatol Int. 2017 Jan;37(1):85-95
pubmed: 27405985
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Exp Dermatol. 2011 Sep;20(9):764-6
pubmed: 21615510